The drugs functioning as cholinesterase inhibitors (CIs) have been found to reduce the cholinergic deficit in Alzheimer’s disease (AD) by restoring synaptic acetylcholine (ACh). This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.